Ruxolitinib
Approved, for something elseMeasured in people, not heightBy mouthSmall moleculeAlso Jakafi, Opzelura
A blood-cancer and transplant-complication drug that blocks the enzyme growth hormone's signal runs through.
A JAK inhibitor. Approved for intermediate or high-risk myelofibrosis and for polycythaemia vera in adults, and for steroid-refractory acute graft-versus-host disease and chronic graft-versus-host disease after one or two prior lines in adults and children aged 12 and over.
Risks. The tablet has no boxed warning, but its label warns of low blood counts, infections, heart problems, clots and cancers, and does not cover children for two of its uses. The cream carries the strongest class of warning, for the same kinds of harm.
On this page
- At the growth plate, members only
- Risks and side effects, members only
The rest of this page is for members
What has been measured, in whom, with every source, and what it does to the rest of you. And every article in the library.
Join for $11.99Lifetime · 3 of 10 founding spots left
Tax is added at checkout (VAT/GST where it applies).
Renews every month at the current price plus tax until you cancel. Cancel from your account before the next monthly charge to stop it.
Card purchases are sold and charged by Link (Stripe) under Link's terms and refund policy.
Already a member? Sign in
Educational content, not medical advice. Nothing here is a recommendation to take or stop taking anything — talk to a doctor about your own situation.